Compare · ARGX vs IMA
ARGX vs IMA
Side-by-side comparison of argenx SE (ARGX) and ImageneBio Inc. (IMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $62.75B, about 983.7x IMA ($63.8M).
- Over the past year, ARGX is up 50.8% and IMA is down 61.8% - ARGX leads by 112.6 points.
- IMA has been more active in the news (15 items in the past 4 weeks vs 11 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 3 for IMA).
- Company
- argenx SE
- ImageneBio Inc.
- Price
- $1021.83+1.03%
- $5.62+1.08%
- Market cap
- $62.75B
- $63.8M
- 1M return
- +14.85%
- -4.75%
- 1Y return
- +50.81%
- -61.77%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 11
- 15
- Recent ratings
- 25
- 3
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest IMA
- H.C. Wainwright initiated coverage on ImageneBio with a new price target
- Chief Executive Officer Yarema Kristin was granted 254,800 shares, increasing direct ownership by 107% to 493,705 units (SEC Form 4)
- Chief Financial Officer Grant-Huerta Yanina was granted 104,000 shares (SEC Form 4)
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form EFFECT filed by ImageneBio Inc.
- SEC Form S-8 filed by ImageneBio Inc.
- SEC Form S-3 filed by ImageneBio Inc.
- SEC Form POS AM filed by ImageneBio Inc.